tbuckley/cabot-search huggingface dataset:
Minimal hepatic encephalopathy in children with chronic liver disease: Prevalence, pathogenesis and magnetic resonance-based diagnosis
Authors: Anshu Srivastava, Saurabh Chaturvedi, Rakesh Kumar Gupta, Rohan Malik, Amrita Mathias, Naranamangalam R. Jagannathan, Sunil Jain, Chandra Mani Pandey, Surender Kumar Yachha, Ram Kishor Singh Rathore
Journal: Journal of Hepatology (2016)
Defibrotide for the Treatment of Veno-Occlusive Disease Post SCT: Preliminary Results of EU Compassionate Use Program in 332 Patients Confirm Promising Activity and Manageable Toxicity.
Authors: Enric Carreras, Eduardo Olavarria, Benedicte Neven, Johan Maertens, Jaap J. Boelens, Francesco Tescione, Margaret Hoyle, Laura I. Ferro, Massimo Iacobelli, Tapani Ruutu, Dietger Niederwieser
Journal: Blood (2007)
Laboratory diagnosis of pneumonia in the molecular age
Authors: Antoni Torres, Nelson Lee, Catia Cilloniz, Jordi Vila, Menno Van der Eerden
Journal: European Respiratory Journal (2016)

Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality. Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical management of pneumonia patients and is a big challenge for conventional microbiological methods. The development and implementation of molecular diagnostic tests for pneumonia has been a major advance in the microbiological diagnosis of respiratory pathogens in recent years. However, with new knowledge regarding the microbiome, together with the recognition that the lungs are a dynamic microbiological ecosystem, our current concept of pneumonia is not totally realistic as this new concept of pneumonia involves a dysbiosis or alteration of the lung microbiome. A new challenge for microbiologists and clinicians has therefore arisen. There is much to learn regarding the information provided by this new diagnostic technology, which will lead to improvements in the time to antibiotic therapy, targeted antibiotic selection and more effective de-escalation and improved stewardship for pneumonia patients. This article provides an overview of current methods of laboratory diagnosis of pneumonia in the molecular age.
Identification and Expression of Two microRNA Primary Transcripts, pri-miR-223 and pri-miR-10a, in Hematopoietic Cell Lines during Cytokine-Stimulated Differentiation.
Authors: Nobuyoshi Kosaka, Keiichi Sugiura, Nami Nogawa, Norio Komatsu, Takashi Kato
Journal: Blood (2005)
HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.
Authors: Vincent T. Ho, Haesook T. Kim, Sarah Windawi, Deborah Liney, Edgar Milford, John Gribben, Corey Cutler, Stephanie J. Lee, Joseph H. Antin, Robert J. Soiffer, Edwin P. Alyea
Journal: Blood (2005)
Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by a cyclooxygenase 2 inhibitor (Celecoxib) and a 5-lipoxygenase inhibitor (Zileuton).
Authors: Ning Li, Sandeep Sood, Mingzhu Fang, Su Wang, Chung S. Yang, Xiaoxin Chen
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

2361 

Previous studies have suggested an important role of aberrant arachidonic acid (AA) metabolism, especially the cyclooxygenase (Cox) and 5-lipoxygenase (5-Lox) pathways, in oral carcinogenesis. Overexpression of cyclooxygenase 2 (Cox2), and overproduction of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) have been clearly demonstrated in human oral cancers. Indomethacin and aspirin (non-specific Cox inhibitors) and curcumin (a dietary inhibitor of AA metabolism) exerted chemopreventive effects in the DMBA-induced oral carcinogenesis in hamster cheek pouch. In this study, we studied the effects of Celecoxib (a specific Cox2 inhibitor) and Zileuton (a specific 5-Lox inhibitor) on DMBA-induced oral carcinogenesis in hamsters. DMBA (0.5% in mineral oil, 0.1ml) was applied topically to the left cheek pouch of male Syrian golden hamsters 3 times/week for 6 weeks. The animals then received topical application (3 times/week) of Celecoxib (3% and 6%, 0.1ml), Zileuton (3% and 6%, 0.1ml), a combination of Celecoxib and Zileuton (both 3%, 0.1ml), or no treatment, for 18 weeks. Celecoxib (6%), Zileuton (6%) and the combination significantly decreased the tumor incidence from 84.6% (22/26) to 56% (14/25, P=0.025), 46.4% (13/28, P=0.003), and 44% (11/25, P=0.002), respectively. The number of tumor was also significantly inhibited by Celecoxib (6%, P=0.01), Zileuton (3%, P=0.02; and 6%, P=0.003) and the combination (P=0.002). All these treatments significantly reduced the tumor volume by 53% (Celecoxib 3%), 63% (Celecoxib 6%), 56% (Zileuton 3%), 74% (Zileuton 6%), and 76% (combination). Tissue levels of PGE2 and LTB4, as determined by enzyme immunoassay, were reduced by Celecoxib and Zileuton, respectively, and were well correlated with the histopathological observations. With in situ hybridization, we found overexpression of Cox2 in the DMBA-treated hamster oral mucosa. Cox2 expression was further enhanced in hyperplasia, dysplasia and squamous cell carcinoma. The results clearly demonstrated that Celecoxib and Zileuton had inhibitory effects against oral carcinogenesis at the post-initiation stage, and such inhibition was related to their specific effects on Cox2 and 5-Lox. (Supported by NIH grant CA101235)
Female Mice With an XY Sex Chromosome Complement Develop Severe Angiotensin II–Induced Abdominal Aortic Aneurysms
Authors: Yasir Alsiraj, Sean E. Thatcher, Richard Charnigo, Kuey Chen, Eric Blalock, Alan Daugherty, Lisa A. Cassis
Journal: Circulation (2016)

Abdominal aortic aneurysms (AAAs) are a deadly pathology with strong sexual dimorphism. Similar to humans, female mice exhibit far lower incidences of angiotensin II-induced AAAs than males. In addition to sex hormones, the X and Y sex chromosomes, and their unique complements of genes, may contribute to sexually dimorphic AAA pathology. Here, we defined the effect of female (XX) versus male (XY) sex chromosome complement on angiotensin II-induced AAA formation and rupture in phenotypically female mice.Female low-density lipoprotein receptor (Ldlr) deficient mice with an XX or XY sex chromosome complement were infused with angiotensin II for 28 days to induce AAAs. Abdominal aortic lumen diameters were quantified by ultrasound, whereas AAA diameters were quantified at study end point. DNA microarrays were performed on abdominal aortas. To mimic males, female mice were administered a single dose of testosterone as neonates or as adults before angiotensin II infusions.Female Ldlr-/- deficient mice with an XX and XY sex chromosome complement had similar sex organ weights and low serum testosterone concentrations. Abdominal aortas from female XY mice selectively expressed Y chromosome genes, whereas genes known to escape X inactivation were higher in XX females. The majority of aortic gene differences in XY versus XX females fell within inflammatory pathways. AAA incidences doubled and aneurysms ruptured in XY females. AAAs from XY females exhibited inflammation, and plasma interleukin-1β concentrations were increased in XY females. Moreover, aortas from XY females had augmented matrix metalloproteinase activity and increased oxidative stress. Last, testosterone exposure applied chronically, or as a single bolus at postnatal day 1, markedly worsened AAA outcomes in XY in comparison with XX adult females.An XY sex chromosome complement in phenotypic females profoundly influenced aortic gene expression profiles and promoted AAA severity. When XY females were exposed to testosterone, aneurysm rupture rates were striking. Mechanisms for augmented AAA severity in XY females include increased inflammation, augmented matrix metalloproteineases, and oxidative stress. Our results demonstrate that genes on the sex chromosomes regulate aortic vascular biology and contribute to sexual dimorphism of AAAs. Sex chromosome genes may serve as novel targets for sex-specific AAA therapeutics.
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Authors: Claudia Zelle-Rieser, Shanmugapriya Thangavadivel, Rainer Biedermann, Andrea Brunner, Patrizia Stoitzner, Ella Willenbacher, Richard Greil, Karin Jöhrer
Journal: Journal of Hematology & Oncology (2016)

Multiple myeloma is an incurable plasma cell malignancy that is mostly restricted to the bone marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor site may be responsible for immune evasion and therapeutical failure of immunotherapies. Therefore, enhanced knowledge about the actual status of T cells in myeloma bone marrow is urgently needed. Here, we assessed the expression of inhibitory molecules PD-1, CTLA-4, 2B4, CD160, senescence marker CD57, and CD28 on T cells of naive and treated myeloma patients in the bone marrow and peripheral blood and collected data on T cell subset distribution in both compartments. In addition, T cell function concerning proliferation and expression of T-bet, IL-2, IFNγ, and CD107a was investigated after in vitro stimulation by CD3/CD28. Finally, data was compared to healthy, age-matched donor T cells from both compartments.Multicolor flow cytometry was utilized for the analyses of surface molecules, intracellular staining of cytokines was also performed by flow cytometry, and proliferation was assessed by 3H-thymidine incorporation. Statistical analyses were performed utilizing unpaired T test and Mann-Whitney U test.We observed enhanced T cell exhaustion and senescence especially at the tumor site. CD8+ T cells expressed several molecules associated with T cell exhaustion (PD-1, CTLA-4, 2B4, CD160) and T cell senescence (CD57, lack of CD28). This phenotype was associated with lower proliferative capacity and impaired function. Despite a high expression of the transcription factor T-bet, CD8+ T cells from the tumor site failed to produce IFNγ after CD3/CD28 in vitro restimulation and displayed a reduced ability to degranulate in response to T cell stimuli. Notably, the percentage of senescent CD57+CD28- CD8+ T cells was significantly lower in treated myeloma patients when compared to untreated patients.T cells from the bone marrow of myeloma patients were more severely impaired than peripheral T cells. While our data suggest that terminally differentiated cells are preferentially deleted by therapy, immune-checkpoint molecules were still present on T cells supporting the potential of checkpoint inhibitors to reactivate T cells in myeloma patients in combination therapies. However, additional avenues to restore anti-myeloma T cell responses are urgently needed.
RTRB-19LOW-DOSE RATE STEREOTACTIC BRACHYTHERAPY IN RECURRENT HIGH GRADE GLIOMA: FEASIBILITY AND OUTCOME IN 227 PATIENTS
Authors: Bogdana Suchorska, Philipp Kickingereder, Christina Hamisch, Martin Kocher, Harald Treuer, Juergen Voges, Maximilian Ruge
Journal: Neuro-Oncology (2015)

BACKGROUND: Despite several advances in the management of malignant glioma, treatment options in case of tumor recurrence after multimodal treatment are limited. The present study reports feasibility and outcome of low-dose rate stereotactic brachytherapy (SBT) with iodine 125 seeds in a patient cohort with inoperable circumscribed recurrent WHO III or IV gliomas. METHODS: Patients with either an anaplastic glioma or glioblastoma who received SBT in case of a tumor recurrence were retrospectively analyzed. SBT was performed according to a prospective protocol established since 1990 at our institution* using iodine-125 seeds for low dose rate implantation. Tumor recurrence was verified histologically prior to seed implantation in all patients. Survival analysis was performed using Cox-regression models to identify prognostic factors for post-recurrence survival (PRS). RESULTS: A total number of 227 patients (83 WHO III and 144 WHO IV) were included. Median follow-up time was 132.2 months. Age at implantation was 49.5 years, Karnofsky performance score (KPS) was 80%, tumor surface dose was 60 Gy and the tumor volume was 17.8 cm3 (median). Median PRS was 14.0 (CI95% 12.4-15.7) months in the entire group; 28.0 (CI 95% 20.2.-35.9) months for WHO III and 11.3 (CI95% 8.8-12.9) months for WHO IV tumors (log rank p <0.0001). In the Cox regression analysis, variables associated with improved PRS following SBT were WHO III histology (p <0.0001), lower age (p = 0.004), higher KPS (p = 0.0017) and lower seed activity (p = 0.027). No permanent morbidity occurred; transient morbidity was observed in 6.9 % of all patients. CONCLUSIONS: In patients with a circumscribed high grade glioma recurrence following multimodal therapy, SBT is a safe and effective therapy option permitting further salvage therapies. *institution of affiliation Nr. 2
Assessing the Patient With Arthralgia, Fevers, and Rash—In Reply
Authors: Zaid S. Ardalan, Abhinav Vasudevan, Adam Testro
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease
Authors: Gilles Andre Salles, Franck Morschhauser, Guillaume Cartron, Thierry Lamy, Noel-Jean Milpied, Catherine Thieblemont, Hervé Tilly, Joe Birkett, Mike Burgess
Journal: Blood (2008)
Human Facilitating Cells (FCs): Two Distinct, Complementary, and Synergistic CD56 Subpopulations That Uniquely Define FC Function
Authors: Yiming Huang, Mary J Elliott, Thomas O Miller, Janina Ratajczak, Larry D Bozulic, Yujie Wen, Hong Xu, Mariusz Z Ratajczak, Suzanne T. Ildstad
Journal: Blood (2014)
PRE-SEASON MOTOR PERFORMANCE RELEVANT TO KNEE INJURY CONTROL IN AN ENGLISH ADULT NETBALL CLUB: A DESCRIPTIVE STUDY
Authors: EM Mullally, CM King, SC Davies, AM Mooney, NC Clark
Journal: British Journal of Sports Medicine (2016)

Noncontact knee injuries are common in netball and can result in major disability and socioeconomic burden. Different types of single-leg balance (SLB) and single-leg hop (SLH) test have been widely used in a variety of knee sports medicine contexts. Knowledge of SLB and SLH test performance can help inform the clinician regarding an athlete's risk of knee injury. There is, however, a gap in the scientific literature regarding SLB and SLH test performance in adult netball players. Therefore, the purpose of this study was to describe pre-season performance of a battery of SLB and SLH tests considered clinically important in knee injury control in an English adult netball club. The Illinois Agility Test (IAT) was also performed to represent netball-related agility. After university ethics approval was obtained and informed consent completed, 23 female netball players participated (mean±standard deviation (SD): age 29±6 y; height 171.6±7.0 cm; mass 68.2±9.8 kg; defence n=10; centre n=2; attack n=11). All reported being uninjured, available for selection and registered for pre-season training. Test order was: barefoot eyes closed balance (ECB; sec), shod triple hop for distance (THD; cm), single hop for distance (SHD; cm) and vertical hop (VH; cm). Leg order was right (R), left (L). The IAT was conducted last. Practice trials and then three measured trials were performed. Appropriate between-trial rest periods were ensured. All tests have previously reported reliability. The mean of measured trials was used for descriptive statistics. All players successfully completed all tests. Mean±SD values were: ECB, R 22.5±15.8 s, L 29.6±15.5 s; THD, R 463.1±53.2 cm, L 464.6±38.7 cm; SHD, R 167.0±18.0 cm, L 166.4±15.7 cm; VH, R 20.0±3.7 cm, L 19.5±3.1 cm; IAT, 19.5±1.3 sec. Across all tests, mean data were comparable to mean data published by other research groups for females of similar age playing in other agility-focused team sports at similar levels of competition. Because the present data were comparable to data from other research groups, the present data were accepted and corroborated as a representation of the motor performances contained within each of the tests. The present and new data can, therefore, be used at several points during the knee injury control decision-making process for adult female netball players.
High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy
Authors: Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin, Joshua J. Meeks
Journal: Journal of the National Comprehensive Cancer Network (2016)

Radical cystectomy (RC) is used to treat select patients with T1 high-grade (T1HG) bladder cancer. However, population-level utilization trends and outcomes for these patients are not well-known. We sought to evaluate treatment patterns and clinicopathologic outcomes of RC for T1HG bladder cancer.Using the National Cancer Data Base (NCDB) for 1998-2012, we conducted a retrospective cohort study of patients with clinical T1HG bladder cancer. The prevalence of RC used to treat T1HG bladder cancer from 1998-2012 was determined. For years 2010-2012, demographic and cancer-related factors were described and regression analysis was used to examine associations with RC. Oncologic outcomes of RC were described and related to mortality using Cox proportional hazards regression.Treatment of T1HG bladder cancer with RC nearly doubled, from 5.5% during 1998-2000 to 9.9%, during 2010-2012. For 2010-2012, 18,277 patients with T1HG bladder cancer were analyzed. Patients who underwent RC were younger, had fewer comorbidities, and were more often treated at an academic center than those who did not undergo RC. At the time of RC, 41% of patients with T1HG bladder cancer were upstaged (pT2 or greater) and 12.7% had lymph node metastases. The 1- and 3-year survival rates were 0.89 and 0.68, respectively. Extravesical (T3+) disease at RC had the strongest independent hazard (hazard ratio [HR], 2.32; 95% CI, 1.72-3.11) of death other than age of 82 years or older (HR, 3.40; 95% CI, 2.28-5.07).The use of RC for T1HG bladder cancer has increased in prevalence in recent years but is still not widely used. There are concerning pathologic outcomes in patients with clinical T1HG bladder cancer treated with RC, including high rates of pathologic upstaging and nodal metastases. Future studies are necessary to better risk-stratify patients with T1HG bladder cancer to best select those who will benefit from aggressive therapy with RC.
Outcome of Second Allogeneic SCT Following Relapse of Hematological Malignancies After a First Allogeneic SCT
Authors: Guillermo Orti, Jaime Sanz, Arancha Bermudez, Dolores Caballero, Carmen Martinez, Jordi Sierra, José R. Cabrera Marin, Ildefonso Espigado, Carlos Solano, Christelle Ferrà, Ana García-Noblejas, Santiago Jimenez, Antonia Sampol, Monica Lopez Duarte, Valentin Garcia, Maria Jesus Pascual, Manuel Jurado, José M. Moraleda, Miguel A. Sanz, Enric Carreras, Rafael F. Duarte
Journal: Blood (2011)
Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.
Authors: George Somlo, Dajun Qian, Firoozeh Sahebi, Neil Martin Kogut, Roberto Rodriguez, Pablo Miguel Parker, Leslie Popplewell, Amrita Krishnan, Joycelynne Palmer, Anthony Selwyn Stein, Ricardo Spielberger, Jeffrey Schriber, Joseph Alvarnas, Warren Chow, Auayporn Nademanee, Jasmine M. Zain, Margaret R. O’Donnell, Stephen J. Forman
Journal: Blood (2006)
Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.
Authors: Roland Fenk, Mark Michael, Fabian Zohren, Thorsten Graef, Arkosch Czibere, Sebastian Balleisen, Frank Neumann, Ulrich-Peter Rohr, Ulrich Steidl, Rainer Haas, Guido Kobbe
Journal: Blood (2006)
Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice
Authors: Sameer A. Parikh, Kari Rabe Chaffee, Timothy G. Call, Wei Ding, Jose F. Leis, Asher Chanan-Khan, Deborah A. Bowen, Michael Conte, Daniel L. Van Dyke, Curtis A. Hanson, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Tait D. Shanafelt
Journal: Blood (2015)
Mechanisms of Ascites Development
Authors: Marlys Hearst Witte
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Combination Therapy with CC-5013 (Lenalidomide; Revlimid™) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).
Authors: S. Vincent Rajkumar, Suzanne R. Hayman, Martha Q. Lacy, Angela Dispenzieri, Antje Hoering, Susan M. Geyer, Steven R. Zeldenrust, Philip R. Greipp, Rafael Fonseca, John A. Lust, Stephen J. Russell, Robert A. Kyle, Thomas E. Witzig, Morie A. Gertz
Journal: Blood (2004)
High Dose Therapy and Autologous Hematopoietic Cell Transplantation for Primary Refractory Diffuse Large Cell Non-Hodgkin’s Lymphoma.
Authors: Thai M. Cao, Keith E. Stockerl-Goldstein, Paul D. Cao, Ginna G. Laport, Kevin Sheehan, Judith A. Shizuru, Laura J. Johnston, Robert S. Negrin, Robert Lowsky
Journal: Blood (2006)
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016
Authors: Xiaoyu Qu, Hongli Li, Rita M. Braziel, Verena Passerini, Lisa M. Rimsza, Eric D. Hsi, John P. Leonard, Sonali M. Smith, Robert Kridel, Oliver Press, Oliver Weigert, Michael LeBlanc, Jonathan W. Friedberg, Min Fang
Journal: Blood (2018)
Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age
Authors: Naval G. Daver, Kiran Naqvi, Tapan M. Kadia, Courtney D. DiNardo, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naveen Pemmaraju, Mark Brandt, Susan O'Brien, Guillermo Garcia-Manero, Sherry R. Pierce, Elias Jabbour, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2013)